Short answer
UNITED THERAPEUTICS Corp (UTHR) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 1.01 (Entry into a Material Definitive Agreement). Board authorized $2.0B share repurchase program on March 8, 2026, valid through March 9, 2027.
UNITED THERAPEUTICS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Board authorized $2.0B share repurchase program on March 8, 2026, valid through March 9, 2027
- $1.5B immediately deployed via two ASR agreements with Citibank: $750M uncollared + $750M collared, upfront payment due March 11, 2026
- Uncollared ASR delivers ~992,120 shares initially (70% of estimated total), final count set by VWAP less discount; settles Q2 2026
- Collared ASR delivers ~708,657 shares initially (50% of estimated total), with price protection via collar provision; settles Q3 2026
- Remaining $500M of the $2.0B authorization available for future repurchases beyond the ASR agreements
Item 7.01 · Regulation FD Disclosure
- Filing mechanics only: exhibit furnished (not filed) under Reg FD, limiting SEC liability exposure; no operational or financial data disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UNITED THERAPEUTICS Corp 8-K filings
Get the next UTHR 8-K as it lands
Follow UTHR for push alerts, or ask the research agent what this filing means.